Referenzliste

[1] Landis, S. H.; Murray, T.; Bolden, S. und Wingo, P. A. (1999): Cancer statistics, 1999, CA Cancer J.Clin. 49 [1], Seite 8-31, 1.

[2] Smith, J. S. und Jenkins, R. B. (2000): Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications, Front Biosci. 5, Seite D213-D231.

[3] Polednak, A. P. und Flannery, J. T. (1995): Brain, other central nervous system, and eye cancer, Cancer 75 [1 Suppl], Seite 330-337.

[4] Dumas-Duport, C.; Scheithauer, B.; O'Fallon, J. und Kelly, P. (1988): Grading of astrocytomas. A simple and reproducible method, Cancer 62 [10], Seite 2152-2165.

[5] Shapiro, J. R. (2002): Genetic alterations associated with adult diffuse astrocytic tumors, Am.J.Med.Genet. 115 [3], Seite 194-201.

[6] Yarden, Y. und Ullrich, A. (1988): Growth factor receptor tyrosine kinases, Annu.Rev.Biochem. 57, Seite 443-478.

[7] Ekstrand, A. J.; James, C. D.; Cavenee, W. K.; Seliger, B.; Pettersson, R. F. und Collins, V. P. (1991): Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo, Cancer Res. 51 [8], Seite 2164-2172.

[8] von, Deimling A.; Louis, D. N.; von, Ammon K.; Petersen, I.; Hoell, T.; Chung, R. Y.; Martuza, R. L.; Schoenfeld, D. A.; Yasargil, M. G.; Wiestler, O. D. und . (1992): Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme, J.Neurosurg. 77 [2], Seite 295-301.

[9] Wong, A. J.; Bigner, S. H.; Bigner, D. D.; Kinzler, K. W.; Hamilton, S. R. und Vogelstein, B. (1987): Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification, Proc.Natl.Acad.Sci.U.S.A 84 [19], Seite 6899-6903.

[10] Ekstrand, A. J.; Sugawa, N.; James, C. D. und Collins, V. P. (1992): Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails, Proc.Natl.Acad.Sci.U.S.A 89 [10], Seite 4309-4313.

[11] Wikstrand, C. J.; McLendon, R. E.; Friedman, A. H. und Bigner, D. D. (1997): Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII, Cancer Res. 57 [18], Seite 4130-4140.

[12] Albarosa, R.; Colombo, B. M.; Roz, L.; Magnani, I.; Pollo, B.; Cirenei, N.; Giani, C.; Conti, A. M.; DiDonato, S. und Finocchiaro, G. (1996): Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q, Am.J.Hum.Genet. 58 [6], Seite 1260-1267.

[13] Ichimura, K.; Schmidt, E. E.; Miyakawa, A.; Goike, H. M. und Collins, V. P. (1998): Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades, Genes Chromosomes.Cancer 22 [1], Seite 9-15.

[14] Karlbom, A. E.; James, C. D.; Boethius, J.; Cavenee, W. K.; Collins, V. P.; Nordenskjold, M. und Larsson, C. (1993): Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10, Hum.Genet. 92 [2], Seite 169-174.

[15] Kimmelman, A. C.; Ross, D. A. und Liang, B. C. (1996): Loss of heterozygosity of chromosome 10p in human gliomas, Genomics 34 [2], Seite 250-254.

[16] Ransom, D. T.; Ritland, S. R.; Moertel, C. A.; Dahl, R. J.; O'Fallon, J. R.; Scheithauer, B. W.; Kimmel, D. W.; Kelly, P. J.; Olopade, O. I.; Diaz, M. O. und . (1992): Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas, Genes Chromosomes.Cancer 5 [4], Seite 357-374.

[17] Rasheed, B. K.; Fuller, G. N.; Friedman, A. H.; Bigner, D. D. und Bigner, S. H. (1992): Loss of heterozygosity for 10q loci in human gliomas, Genes Chromosomes.Cancer 5 [1], Seite 75-82.

[18] Schmidt, E. E.; Ichimura, K.; Reifenberger, G. und Collins, V. P. (1994): CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas, Cancer Res. 54 [24], Seite 6321-6324.

[19] Cantley, L. C. und Neel, B. G. (1999): New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway, Proc.Natl.Acad.Sci.U.S.A 96 [8], Seite 4240-4245.

[20] Bouvier-Labit, C.; Chinot, O.; Ochi, C.; Gambarelli, D.; Dufour, H. und Figarella-Branger, D. (1998): Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas, Neuropathol.Appl.Neurobiol. 24 [5], Seite 381-388.

[21] Dorward, N. L.; Hawkins, R. A. und Whittle, I. R. (1993): Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma, Br.J.Neurosurg. 7 [2], Seite 197-199.

[22] Jaros, E.; Perry, R. H.; Adam, L.; Kelly, P. J.; Crawford, P. J.; Kalbag, R. M.; Mendelow, A. D.; Sengupta, R. P. und Pearson, A. D. (1992): Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours, Br.J.Cancer 66 [2], Seite 373-385.

[23] Kordek, R.; Biernat, W.; Alwasiak, J.; Maculewicz, R.; Yanagihara, R. und Liberski, P. P. (1995): p53 protein and epidermal growth factor receptor expression in human astrocytomas, J.Neurooncol. 26 [1], Seite 11-16.

[24] Leenstra, S.; Bijlsma, E. K.; Troost, D.; Oosting, J.; Westerveld, A.; Bosch, D. A. und Hulsebos, T. J. (1994): Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis, Br.J.Cancer 70 [4], Seite 684-689.

[25] Leenstra, S.; Oskam, N. T.; Bijleveld, E. H.; Bosch, D. A.; Troost, D. und Hulsebos, T. J. (1998): Genetic sub-types of human malignant astrocytoma correlate with survival, Int.J.Cancer 79 [2], Seite 159-165.

[26] Rainov, N. G.; Dobberstein, K. U.; Bahn, H.; Holzhausen, H. J.; Lautenschlager, C.; Heidecke, V. und Burkert, W. (1997): Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival, J.Neurooncol. 35 [1], Seite 13-28.

[27] Schlegel, J.; Merdes, A.; Stumm, G.; Albert, F. K.; Forsting, M.; Hynes, N. und Kiessling, M. (1994): Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma, Int.J.Cancer 56 [1], Seite 72-77.

[28] Schober, R.; Bilzer, T.; Waha, A.; Reifenberger, G.; Wechsler, W.; von, Deimling A.; Wiestler, O. D.; Westphal, M.; Kemshead, J. T.; Vega, F. und . (1995): The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial, Clin.Neuropathol. 14 [3], Seite 169-174.

[29] Waha, A.; Baumann, A.; Wolf, H. K.; Fimmers, R.; Neumann, J.; Kindermann, D.; Astrahantseff, K.; Blumcke, I.; von, Deimling A. und Schlegel, U. (1996): Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas, J.Neurosurg. 85 [4], Seite 634-641.

[30] Kreth, F. W.; Warnke, P. C.; Scheremet, R. und Ostertag, C. B. (1993): Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme, J.Neurosurg. 78 [5], Seite 762-766.

[31] Kreth, F. W.; Berlis, A.; Spiropoulou, V.; Faist, M.; Scheremet, R.; Rossner, R.; Volk, B. und Ostertag, C. B. (1999): The role of tumor resection in the treatment of glioblastoma multiforme in adults, Cancer 86 [10], Seite 2117-2123.

[32] Barker, F. G.; Prados, M. D.; Chang, S. M.; Gutin, P. H.; Lamborn, K. R.; Larson, D. A.; Malec, M. K.; McDermott, M. W.; Sneed, P. K.; Wara, W. M. und Wilson, C. B. (1996): Radiation response and survival time in patients with glioblastoma multiforme, J.Neurosurg. 84 [3], Seite 442-448.

[33] Wisoff, J. H.; Boyett, J. M.; Berger, M. S.; Brant, C.; Li, H.; Yates, A. J.; Guire-Cullen, P.; Turski, P. A.; Sutton, L. N.; Allen, J. C.; Packer, R. J. und Finlay, J. L. (1998): Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945, J.Neurosurg. 89 [1], Seite 52-59.

[34] Lacroix, M.; bi-Said, D.; Fourney, D. R.; Gokaslan, Z. L.; Shi, W.; DeMonte, F.; Lang, F. F.; McCutcheon, I. E.; Hassenbusch, S. J.; Holland, E.; Hess, K.; Michael, C.; Miller, D. und Sawaya, R. (2001): A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J.Neurosurg. 95 [2], Seite 190-198.

[35] Metcalfe, S. E. und Grant, R. (2001): Biopsy versus resection for malignant glioma, Cochrane.Database.Syst.Rev. [3], Seite CD002034.

[36] Iwama, T.; Yamada, H.; Sakai, N.; Andoh, T.; Nakashima, T.; Hirata, T. und Funakoshi, T. (1991): Correlation between magnetic resonance imaging and histopathology of intracranial glioma, Neurol.Res. 13 [1], Seite 48-54.

[37] Tovi, M.; Hartman, M.; Lilja, A. und Ericsson, A. (1994): MR imaging in cerebral gliomas. Tissue component analysis in correlation with histopathology of whole-brain specimens, Acta Radiol. 35 [5], Seite 495-505.

[38] Vaquero, J.; Martinez, R. und Manrique, M. (2000): Stereotactic biopsy for brain tumors: is it always necessary?, Surg.Neurol. 53 [5], Seite 432-437.

[39] Glinski, B. (1993): Postoperative hypofractionated radiotherapy versus conventionally fractionated radiotherapy in malignant gliomas. A preliminary report on a randomized trial, J.Neurooncol. 16 [2], Seite 167-172.

[40] Lei, Y. H. (1990): [Combined surgery and radiotherapy of glioblastoma multiforme--report of 73 cases], Zhonghua Zhong.Liu Za Zhi. 12 [6], Seite 469-471.

[41] Lutterbach, J.; Weigel, P.; Guttenberger, R. und Hinkelbein, W. (1999): Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme, Radiother.Oncol. 53 [1], Seite 49-52.

[42] Mayer, E. G.; Boone, M. L. und Aristizabal, S. A. (1976): Role of radiation therapy in the management of neoplasms of the central nervous system, Adv.Neurol. 15, Seite 201-220.

[43] Barker, F. G.; Chang, S. M.; Larson, D. A.; Sneed, P. K.; Wara, W. M.; Wilson, C. B. und Prados, M. D. (2001): Age and radiation response in glioblastoma multiforme, Neurosurgery 49 [6], Seite 1288-1297.

[44] Forth, W.; Henschler, D. und Rummel, W. (1998): Allgemeine und spezielle Pharmakologie und Toxikologie.

[45] Walker, M. D.; Green, S. B.; Byar, D. P.; Alexander E Jr; Batzdorf, U.; Brooks, W. H.; Hunt, W. E.; MacCarty, C. S.; Mahaley, M. S., Jr.; Mealey, J., Jr.; Owens, G.; Ransohoff, J.; Robertson, J. T.; Shapiro, W. R.; Smith, K. R., Jr.; Wilson, C. B. und Strike, T. A. (1980): Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery, N.Engl.J.Med. 303 [23], Seite 1323-1329.

[46] Wiestler, O.; Kleihues, P. und Pegg, A. E. (1984): O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors, Carcinogenesis 5 [1], Seite 121-124.

[47] Kat, A.; Thilly, W. G.; Fang, W. H.; Longley, M. J.; Li, G. M. und Modrich, P. (1993): An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair, Proc.Natl.Acad.Sci.U.S.A 90 [14], Seite 6424-6428.

[48] Koi, M.; Umar, A.; Chauhan, D. P.; Cherian, S. P.; Carethers, J. M.; Kunkel, T. A. und Boland, C. R. (1994): Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation, Cancer Res. 54 [16], Seite 4308-4312.

[49] Schold, S. C., Jr.; Brent, T. P.; von, Hofe E.; Friedman, H. S.; Mitra, S.; Bigner, D. D.; Swenberg, J. A. und Kleihues, P. (1989): O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts, J.Neurosurg. 70 [4], Seite 573-577.

[50] Friedman, H. S.; Kerby, T. und Calvert, H. (2000): Temozolomide and treatment of malignant glioma, Clin.Cancer Res. 6 [7], Seite 2585-2597.

[51] Engelhard, H. H. (2000): The role of interstitial BCNU chemotherapy in the treatment of malignant glioma, Surg.Neurol. 53 [5], Seite 458-464.

[52] Fine, H. A.; Dear, K. B.; Loeffler, J. S.; Black, P. M. und Canellos, G. P. (1993): Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults, Cancer 71 [8], Seite 2585-2597.

[53] Taschner, C. A. (2000): Zur Integration der funktionellen Magnetresonanztomographie in die navigierte Therapie cerebraler Tumoren.

[54] Olzowy, B.; Hundt, C. S.; Stocker, S.; Bise, K.; Reulen, H. J. und Stummer, W. (2002): Photoirradiation therapy of experimental malignant glioma with 5-aminolevulinic acid, J.Neurosurg. 97 [4], Seite 970-976.

[55] Brandes, A. A.; Vastola, F.; Basso, U.; Berti, F.; Pinna, G.; Rotilio, A.; Gardiman, M.; Scienza, R.; Monfardini, S. und Ermani, M. (2003): A prospective study on glioblastoma in the elderly, Cancer 97 [3], Seite 657-662.

[56] Brandes, A. A.; Scelzi, E.; Zampieri, P.; Rigon, A.; Rotilio, A.; Amista, P.; Berti, F. und Fiorentino, M. V. (1997): Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas, Am.J.Clin.Oncol. 20 [4], Seite 364-367.

[57] Burton, E. C. und Prados, M. D. (2000): Malignant gliomas, Curr.Treat.Options.Oncol. 1 [5], Seite 459-468.

[58] van den Bent, M. J.; Schellens, J. H.; Vecht, C. J.; Sillevis Smit, P. A.; Loosveld, O. J.; Ma, J.; Tijssen, C. C.; Jansen, R. L.; Kros, J. M. und Verweij, J. (1998): Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas, Eur.J.Cancer 34 [10], Seite 1570-1574.

[59] Prados, M. D. und Russo, C. (1998): Chemotherapy of brain tumors, Semin.Surg.Oncol. 14 [1], Seite 88-95.

[60] Green, S. B.; Byar, D. P.; Walker, M. D.; Pistenmaa, D. A.; Alexander E Jr; Batzdorf, U.; Brooks, W. H.; Hunt, W. E.; Mealey, J., Jr.; Odom, G. L.; Paoletti, P.; Ransohoff, J.; Robertson, J. T.; Selker, R. G.; Shapiro, W. R.; Smith, K. R., Jr.; Wilson, C. B. und Strike, T. A. (1983): Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma, Cancer Treat.Rep. 67 [2], Seite 121-132.

[61] Prados, M. D. und Levin, V. (2000): Biology and treatment of malignant glioma, Semin.Oncol. 27 [3 Suppl 6], Seite 1-10.

[62] Nieder, C.; Grosu, A. L. und Molls, M. (2000): A comparison of treatment results for recurrent malignant gliomas, Cancer Treat.Rev. 26 [6], Seite 397-409.

[63] Ammirati, M.; Vick, N.; Liao, Y. L.; Ciric, I. und Mikhael, M. (1987): Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas, Neurosurgery 21 [2], Seite 201-206.

[64] Castro, M. G.; Cowen, R.; Williamson, I. K.; David, A.; Jimenez-Dalmaroni, M. J.; Yuan, X.; Bigliari, A.; Williams, J. C.; Hu, J. und Lowenstein, P. R. (2003): Current and future strategies for the treatment of malignant brain tumors, Pharmacol.Ther. 98 [1], Seite 71-108.

[65] Bleehen, N. M.; Freedman, L. S. und Stenning, S. P. (1989): A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party, Int.J.Radiat.Oncol.Biol.Phys. 16 [4], Seite 1077-1081.